Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: NonValvular Atrial Fibrillation

Treatments: Drug: Eliquis

Study type: Observational

Funder types: Industry

Identifiers

NCT02007655

CV185-286

Details and patient eligibility

About

The primary objectives of this study are:

• To estimate the incidence rate of unexpected adverse events
• To characterize the bleeding events and assess risk factors of bleeding
• To identify ancillary baseline variables that may also be associated with adverse outcomes

Enrollment: 6,372 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Patients who are beginning to receive the treatment with this product under the approved indications, dosage, and administration will be included in this study

Exclusion Criteria:

• Patients who are receiving Eliquis outside of its approved indication will be excluded from this study

Trial design

6,372 participants in 1 patient group

Eliquis on Nonvalvular Atrial Fibrilliation patients

Description:

Patients who are beginning to receive the treatment with Eliquis under the approved indications, dosage, and administration will be included in this study

Treatment:

Drug: Eliquis